Pharmaceutical Executive October 12, 2023
Mike Hollan

A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.

About the speaker

David Benshoof Klein is a healthcare investor and entrepreneur with over 20 years of life science industry experience. Before co-founding Click Therapeutics, David was the former Managing Director at Opus Point Partners which created, financed, and operated 10+ science companies including Cougar Biotechnology (Acquired by J&J), Chelsea Therapeutics (Acquired by Lundbeck), TG Therapeutics...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Apps, Conferences / Podcast, Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Trends
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article